Dated June 4, 2018 - and - COLLABORATION AGREEMENT FOR THE PROPOSED “CHEMERIN” PROGRAMCollaboration Agreement • November 10th, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • New York
LICENSE AGREEMENTLicense Agreement • November 10th, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“Agreement”) is made effective as of May 1, 2018 (“Effective Date”) by and between on the one hand Tufts Medical Center, Inc., 800 Washington Street, Boston, MA 02111 (the “Licensor”), and , OKYO PHARMA LIMITED, whose registered office is at Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB (“Licensee’’). Licensor and Licensee are each hereafter referred to individually as a “Party’’ and together as the “Parties.”
Dated 2018 -and - AMENDMENT TO COLLABORATION AGREEMENT Cooley Cooley (UK) LLP, DASHWOOD, 98 OLD BROAD STREET, LONDON EX2M 1QS, UKCollaboration Agreement • November 10th, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • New York
LICENSE AND SUBLlCENSE AGREEMENTLicense and Subllcense Agreement • November 10th, 2021 • OKYO Pharma LTD • Biological products, (no disgnostic substances) • Delaware
This License and Sublicense Agreement (“Agreement”) is made effective as of May 22, 2017 (“Effective Date”) by and between on the one hand On Target Therapeutics, LLC, 1S Wynnewood Road, Wellesley, MA 02481 (“On Target” or ‘‘Licensor’’), and Biovitas Capital, 18 South Street, Mayfair, London, W1K 1DG, UK (“Licensee”). Licensor and Licensee are each hereafter referred to individually as a “Party” and together as the “Parties.”
